Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Cancer Extensive Stage

Small Cell Lung Cancer Limited Stage

Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Lung Neoplasms

Small Cell Lung Carcinoma

Advanced Non-squamous Non-small-cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma of Lung

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Lung Neoplasms

Small Cell Lung Carcinoma

Lung Neoplasms

Lung Neoplasms

Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

Adenocarcinoma of Lung

Lung Neoplasms, Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Adenocarcinoma of Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Neoplasms

Clinical Trials

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer

A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer

LIAES

APPEAL

PASSION

Adebrelimab + Apatinib in SCLC Maintenance Therapy

XQonc-007

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.

SABRE

CAMERA

Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

MK 01

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation

Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer

A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）

Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC

Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer

Spark-AL003

Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)

Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma

Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy

Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)

The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer

Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer

The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer

Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer